CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia
CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia |
|
https://doi.org/10.18632/oncotarget.26383
Anna B. Halpern,
and Roland B. Walter
|
| 36543-36544 |
Cancer immunotherapy: Moving beyond checkpoint inhibition
Cancer immunotherapy: Moving beyond checkpoint inhibition |
|
https://doi.org/10.18632/oncotarget.26384
Marianne Boes
|
| 36545-36546 |
Genomic biomarker of checkpoint efficacy, highways for precision medicine in lung cancer
Genomic biomarker of checkpoint efficacy, highways for precision medicine in lung cancer |
|
https://doi.org/10.18632/oncotarget.26389
Francois Ghiringhelli,
and Caroline Truntzer
|
| 36547-36548 |
Using genomics to better define high-risk MGUS/SMM patients
Using genomics to better define high-risk MGUS/SMM patients |
|
https://doi.org/10.18632/oncotarget.26390
Ankit K. Dutta,
Duncan R. Hewett,
J. Lynn Fink,
and Andrew C.W. Zannettino
|
| 36549-36550 |
IGFBP2 is a potential biomarker in acute kidney injury (AKI) and resveratrol-loaded nanoparticles prevent AKI
IGFBP2 is a potential biomarker in acute kidney injury (AKI) and resveratrol-loaded nanoparticles prevent AKI |
|
https://doi.org/10.18632/oncotarget.25663
Hai-Lun Li,
Zhuan Yan,
Zun-Ping Ke,
Xiao-Feng Tian,
Li-Li Zhong,
Yong-Tao Lin,
Yong Xu,
and Dong-Hui Zheng
|
| 36551-36560 |
Significance of intranuclear angiotensin-II type 2 receptor in oral squamous cell carcinoma
Significance of intranuclear angiotensin-II type 2 receptor in oral squamous cell carcinoma |
|
https://doi.org/10.18632/oncotarget.26337
Sayako Matsushima-Otsuka,
Rina Fujiwara-Tani,
Takamitsu Sasaki,
Hitoshi Ohmori,
Chie Nakashima,
Shingo Kishi,
Yukiko Nishiguchi,
Kiyomu Fujii,
Yi Luo,
and Hiroki Kuniyasu
|
| 36561-36574 |
Preoperative diffusion-weighted magnetic resonance imaging and intraoperative frozen sections for predicting the tumor grade in endometrioid endometrial cancer
Preoperative diffusion-weighted magnetic resonance imaging and intraoperative frozen sections for predicting the tumor grade in endometrioid endometrial cancer |
|
https://doi.org/10.18632/oncotarget.26366
Tomohito Tanaka,
Yoshito Terai,
Satoe Fujiwara,
Yoshimichi Tanaka,
Hiroshi Sasaki,
Satoshi Tsunetoh,
Kazuhiro Yamamoto,
Takashi Yamada,
Yoshifumi Narumi,
and Masahide Ohmichi
|
| 36575-36584 |
Co-treatment of tumor cells with hyaluronan plus doxorubicin affects endothelial cell behavior independently of VEGF expression
Co-treatment of tumor cells with hyaluronan plus doxorubicin affects endothelial cell behavior independently of VEGF expression |
|
https://doi.org/10.18632/oncotarget.26379
Daiana L. Vitale,
Fiorella M. Spinelli,
Daiana Del Dago,
Antonella Icardi,
Gianina Demarchi,
Ilaria Caon,
Mariana García,
Marcela F. Bolontrade,
Alberto Passi,
Carolina Cristina,
and Laura Alaniz
|
| 36585-36602 |
Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC
Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC |
|
https://doi.org/10.18632/oncotarget.26391
Amandine Le Bourgeois,
Myriam Labopin,
Mathieu Leclerc,
Régis Peffault de Latour,
Jean-Henri Bourhis,
Patrice Ceballos,
Corentin Orvain,
Hélène Labussière Wallet,
Karin Bilger,
Didier Blaise,
Marie-Thérese Rubio,
Thierry Guillaume,
Mohamad Mohty,
Patrice Chevallier,
and on behalf of Société Francophone de Greffe de Moelle et de Thérapie Cellulaire
|
| 36603-36612 |
Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia
Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia |
|
https://doi.org/10.18632/oncotarget.26400
Nikhil Patkar,
Rohan Kodgule,
Chinmayee Kakirde,
Goutham Raval,
Prasanna Bhanshe,
Swapnali Joshi,
Shruti Chaudhary,
Y. Badrinath,
Sitaram Ghoghale,
Shraddha Kadechkar,
Syed Hasan Khizer,
Sadhana Kannan,
Dhanalaxmi Shetty,
Anant Gokarn,
Sachin Punatkar,
Hasmukh Jain,
Bhausaheb Bagal,
Hari Menon,
Manju Sengar,
Navin Khattry,
Prashant Tembhare,
Papagudi Subramanian,
and Sumeet Gujral
|
| 36613-36624 |
Meta-analysis of the likelihood of FOXC1 expression in early- and late-stage tumors
Meta-analysis of the likelihood of FOXC1 expression in early- and late-stage tumors |
|
https://doi.org/10.18632/oncotarget.26358
Tsutomu Kume,
and Tarek Shackour
|
| 36625-36630 |
Tumour treating fields in a combinational therapeutic approach
Tumour treating fields in a combinational therapeutic approach |
|
https://doi.org/10.18632/oncotarget.26344
Joshua Branter,
Surajit Basu,
and Stuart Smith
|
| 36631-36644 |
Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth
Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth |
|
https://doi.org/10.18632/oncotarget.26415
Kimberley Hanson,
Stephen D. Robinson,
Karamallah Al-Yousuf,
Adam E. Hendry,
Darren W. Sexton,
Victoria Sherwood,
and Grant N. Wheeler
|
| 36645-36645 |
